For the treatment of GBM, clinical trial results are available for CAR T cells targeting three anti-gens: EGFRvIII, human epidermal growth factor receptor 2 (HER2; also known as ERBB2) and IL-13 receptor α2 (IL-13Rα2) [104]. This evidence concerns the gene ERBB2 and glioblastoma.